Leerink Partnrs Reiterates Outperform Rating for AnaptysBio (NASDAQ:ANAB)

AnaptysBio (NASDAQ:ANAB)‘s stock had its “outperform” rating restated by investment analysts at Leerink Partnrs in a research report issued on Tuesday, Zacks.com reports. Leerink Partnrs also issued estimates for AnaptysBio’s Q1 2024 earnings at ($1.41) EPS, Q2 2024 earnings at ($1.44) EPS, Q3 2024 earnings at ($1.45) EPS, Q4 2024 earnings at ($1.42) EPS, FY2024 earnings at ($5.71) EPS, Q1 2025 earnings at ($1.91) EPS, Q2 2025 earnings at ($1.86) EPS, Q3 2025 earnings at ($1.85) EPS, Q4 2025 earnings at ($1.14) EPS, FY2025 earnings at ($6.37) EPS, FY2026 earnings at ($4.82) EPS, FY2027 earnings at ($3.95) EPS and FY2028 earnings at ($3.39) EPS.

Several other analysts also recently commented on the stock. SVB Leerink assumed coverage on shares of AnaptysBio in a research report on Tuesday. They issued an “outperform” rating and a $47.00 target price for the company. Stifel Nicolaus assumed coverage on shares of AnaptysBio in a report on Wednesday, February 21st. They issued a “buy” rating and a $50.00 price objective for the company. Piper Sandler began coverage on AnaptysBio in a report on Friday, February 16th. They set an “overweight” rating and a $80.00 target price on the stock. Wedbush raised AnaptysBio from a “neutral” rating to an “outperform” rating and boosted their price target for the stock from $20.00 to $34.00 in a research report on Tuesday, March 12th. Finally, JPMorgan Chase & Co. lowered their price objective on AnaptysBio from $30.00 to $28.00 and set a “neutral” rating on the stock in a report on Monday, April 1st. One investment analyst has rated the stock with a sell rating, two have given a hold rating and eight have issued a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $46.22.

AnaptysBio Stock Up 0.6 %

AnaptysBio stock opened at $21.47 on Tuesday. The stock has a market cap of $574.54 million, a P/E ratio of -3.53 and a beta of -0.30. AnaptysBio has a 12 month low of $13.36 and a 12 month high of $27.50. The company’s fifty day simple moving average is $23.38 and its 200-day simple moving average is $20.55.

AnaptysBio (NASDAQ:ANAB) last posted its quarterly earnings results on Monday, March 11th. The biotechnology company reported ($1.59) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.74) by $0.15. The company had revenue of $9.01 million during the quarter, compared to the consensus estimate of $3.28 million. AnaptysBio had a negative return on equity of 119.42% and a negative net margin of 953.66%. On average, equities research analysts expect that AnaptysBio will post -6.25 earnings per share for the current fiscal year.

Insider Buying and Selling at AnaptysBio

In other AnaptysBio news, CEO Daniel Faga sold 3,000 shares of AnaptysBio stock in a transaction that occurred on Monday, March 25th. The stock was sold at an average price of $21.42, for a total value of $64,260.00. Following the transaction, the chief executive officer now directly owns 749,087 shares of the company’s stock, valued at approximately $16,045,443.54. The sale was disclosed in a document filed with the SEC, which is accessible through this link. In other AnaptysBio news, CEO Daniel Faga sold 3,000 shares of the stock in a transaction on Monday, March 25th. The shares were sold at an average price of $21.42, for a total value of $64,260.00. Following the completion of the sale, the chief executive officer now directly owns 749,087 shares of the company’s stock, valued at approximately $16,045,443.54. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Eric J. Loumeau sold 5,000 shares of the business’s stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $25.00, for a total transaction of $125,000.00. Following the transaction, the insider now owns 3,240 shares in the company, valued at approximately $81,000. The disclosure for this sale can be found here. Insiders have sold 157,005 shares of company stock valued at $3,586,199 in the last 90 days. 35.50% of the stock is currently owned by insiders.

Institutional Trading of AnaptysBio

Several institutional investors have recently modified their holdings of the company. Woodline Partners LP lifted its position in AnaptysBio by 125.1% in the second quarter. Woodline Partners LP now owns 1,034,549 shares of the biotechnology company’s stock worth $21,043,000 after purchasing an additional 574,987 shares during the period. First Light Asset Management LLC boosted its position in shares of AnaptysBio by 56.4% during the 4th quarter. First Light Asset Management LLC now owns 1,237,178 shares of the biotechnology company’s stock valued at $26,500,000 after acquiring an additional 446,372 shares in the last quarter. Eventide Asset Management LLC acquired a new stake in shares of AnaptysBio during the 3rd quarter valued at about $7,669,000. Millennium Management LLC increased its stake in AnaptysBio by 1,050.7% in the fourth quarter. Millennium Management LLC now owns 322,802 shares of the biotechnology company’s stock valued at $10,004,000 after acquiring an additional 294,750 shares during the period. Finally, Palo Alto Investors LP lifted its stake in AnaptysBio by 59.3% during the fourth quarter. Palo Alto Investors LP now owns 686,882 shares of the biotechnology company’s stock worth $14,713,000 after purchasing an additional 255,658 shares during the period.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.